Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Expert Rev Clin Pharmacol. 2017 Oct 12;11(2):151–164. doi: 10.1080/17512433.2017.1353909

Figure 4. Clinical outcomes of CYP2C19 LOF genotype-based antiplatelet therapy.

Figure 4

MACE free survival curve from multivariable Cox regression analysis with propensity score adjustment. Patients with CYP2C19 LOF alleles who were treated with alternative antiplatelet therapy (black line) had a significantly lower risk for MACE (major adverse cardiac events) compared to patients with LOF alleles who were treated with clopidogrel (blue line).